- Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
-
Barberio B, Savarino EV, Card T, Canova C, Baldisser F, Gubbiotti A, Massimi D, Ghisa M, Zingone F
- KMID: 2525078
- Intest Res.
- 2022 Jan;20(1):114-123.
- doi: 10.5217/ir.2021.00037
Background/Aims: Current literature is lacking in studies comparing the incidence of adverse events (AEs) in patients with inflammatory bowel diseases (IBD) treated with adalimumab (ADA) or vedolizumab (VDZ) in a... -
- CITED
-
- Close
- SHARE
-
- Close
